174 related articles for article (PubMed ID: 23058107)
21. Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression.
Kim HS; Kim MJ; Kim EJ; Yang Y; Lee MS; Lim JS
Biochem Pharmacol; 2012 Feb; 83(3):385-94. PubMed ID: 22120676
[TBL] [Abstract][Full Text] [Related]
22. Berberine improves kidney function in diabetic mice via AMPK activation.
Zhao L; Sun LN; Nie HB; Wang XL; Guan GJ
PLoS One; 2014; 9(11):e113398. PubMed ID: 25409232
[TBL] [Abstract][Full Text] [Related]
23. Berberine inhibits human colon cancer cell migration via AMP-activated protein kinase-mediated downregulation of integrin β1 signaling.
Park JJ; Seo SM; Kim EJ; Lee YJ; Ko YG; Ha J; Lee M
Biochem Biophys Res Commun; 2012 Oct; 426(4):461-7. PubMed ID: 22943849
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine.
Brusq JM; Ancellin N; Grondin P; Guillard R; Martin S; Saintillan Y; Issandou M
J Lipid Res; 2006 Jun; 47(6):1281-8. PubMed ID: 16508037
[TBL] [Abstract][Full Text] [Related]
25. Protein kinase D activation stimulates the transcription of the insulin receptor gene.
Zhang H; Kong WJ; Shan YQ; Song DQ; Li Y; Wang YM; You XF; Jiang JD
Mol Cell Endocrinol; 2010 Dec; 330(1-2):25-32. PubMed ID: 20674666
[TBL] [Abstract][Full Text] [Related]
26. Total synthesis of epiberberine.
Lu ZM; Liang JQ; Wang HT; Zhao SH; Zhang H; Tu PF
J Asian Nat Prod Res; 2012; 14(9):873-6. PubMed ID: 22924555
[TBL] [Abstract][Full Text] [Related]
27. Discovery of C-9 Modified Berberine Derivatives as Novel Lipid-Lowering Agents.
Li DD; Yu P; Xu H; Wang ZZ; Xiao W; Zhao LG
Chem Pharm Bull (Tokyo); 2021 Jan; 69(1):59-66. PubMed ID: 33087641
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and cholesterol-lowering efficacy for prodrugs of berberrubine.
Li YH; Li Y; Yang P; Kong WJ; You XF; Ren G; Deng HB; Wang YM; Wang YX; Jiang JD; Song DQ
Bioorg Med Chem; 2010 Sep; 18(17):6422-8. PubMed ID: 20673726
[TBL] [Abstract][Full Text] [Related]
29. In vitro cytotoxicity of the protoberberine-type alkaloids.
Iwasa K; Moriyasu M; Yamori T; Turuo T; Lee DU; Wiegrebe W
J Nat Prod; 2001 Jul; 64(7):896-8. PubMed ID: 11473418
[TBL] [Abstract][Full Text] [Related]
30. The pivotal role of protein kinase C zeta (PKCzeta) in insulin- and AMP-activated protein kinase (AMPK)-mediated glucose uptake in muscle cells.
Liu LZ; Cheung SC; Lan LL; Ho SK; Chan JC; Tong PC
Cell Signal; 2010 Oct; 22(10):1513-22. PubMed ID: 20570724
[TBL] [Abstract][Full Text] [Related]
31. Berberine suppresses neuroinflammatory responses through AMP-activated protein kinase activation in BV-2 microglia.
Lu DY; Tang CH; Chen YH; Wei IH
J Cell Biochem; 2010 Jun; 110(3):697-705. PubMed ID: 20512929
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and anticancer activity of a novel series of 9-O-substituted berberine derivatives: a lipophilic substitute role.
Lo CY; Hsu LC; Chen MS; Lin YJ; Chen LG; Kuo CD; Wu JY
Bioorg Med Chem Lett; 2013 Jan; 23(1):305-9. PubMed ID: 23182088
[TBL] [Abstract][Full Text] [Related]
33. Palmatine and berberine isolation artifacts.
Marek R; Seckárová P; Hulová D; Marek J; Dostál J; Sklenár V
J Nat Prod; 2003 Apr; 66(4):481-6. PubMed ID: 12713397
[TBL] [Abstract][Full Text] [Related]
34. Discovery, synthesis, and structure-activity relationships of 20(S)-protopanaxadiol (PPD) derivatives as a novel class of AMPKα2β1γ1 activators.
Liu J; Chen D; Liu P; He M; Li J; Li J; Hu L
Eur J Med Chem; 2014 May; 79():340-9. PubMed ID: 24747289
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, structure-activity relationship and in vitro anti-mycobacterial evaluation of 13-n-octylberberine derivatives.
Liu YX; Xiao CL; Wang YX; Li YH; Yang YH; Li YB; Bi CW; Gao LM; Jiang JD; Song DQ
Eur J Med Chem; 2012 Jun; 52():151-8. PubMed ID: 22503208
[TBL] [Abstract][Full Text] [Related]
36. Antimicrobial activity of some 13-alkyl substituted protoberberinium salts.
Iwasa K; Kamigauchi M; Sugiura M; Nanba H
Planta Med; 1997 Jun; 63(3):196-8. PubMed ID: 9225598
[TBL] [Abstract][Full Text] [Related]
37. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity.
Kim WS; Lee YS; Cha SH; Jeong HW; Choe SS; Lee MR; Oh GT; Park HS; Lee KU; Lane MD; Kim JB
Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E812-9. PubMed ID: 19176354
[TBL] [Abstract][Full Text] [Related]
38. Berberine promotes glucose consumption independently of AMP-activated protein kinase activation.
Xu M; Xiao Y; Yin J; Hou W; Yu X; Shen L; Liu F; Wei L; Jia W
PLoS One; 2014; 9(7):e103702. PubMed ID: 25072399
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and antihyperglycemic evaluation of various protoberberine derivatives.
Bian X; He L; Yang G
Bioorg Med Chem Lett; 2006 Mar; 16(5):1380-3. PubMed ID: 16359864
[TBL] [Abstract][Full Text] [Related]
40. [Regulatory effect of coptisine on key genes involved in cholesterol metabolism].
Chen B; Xue DF; Han B; Kou SM; Ye XL; Li XG
Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(8):1548-53. PubMed ID: 26281596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
